Abstract
The overall tumour incidence and breast cancer incidence related to hormone replacement therapy (HRT) were followed in a population-based cohort of 29 508 women, aged 25–65 when interviewed in 1990–92. By the end of the follow up in December 1999, there were 226 611 person-years of observation. A total of 1145 malignant tumours were recorded (expected 1166.6; SIR = 0.98, 95% CI 0.93–1.04). There was a small excess of breast cancer with 434 observed and 387.69 expected (SIR = 1.12, 95% CI 1.02–1.23). Among about 3 663 ever users of HRT, there was no increase in overall tumour incidence (SIR = 0.98, 95% CI 0.86–1.12) but a significant excess of breast cancer (SIR = 1.35, 95% CI 1.09–1.64) compared with never users (SIR = 1.07, 95% CI 0.96–1.19). Breast cancer increased with increasing duration of use and for 48–120 months use the SIR was 1.92 (95% CI 1.32–2.70). There was no significant interaction with family history of breast cancer although an independent additive effect was suggested between HRT use and family history. In a Cox regression model time to breast cancer in relation to duration of HRT use was analysed adjusting for age at menarche, age at menopause, age at first full term pregnancy, parity and age at diagnosis. A significantly higher risk was seen for longer duration of HRT use compared with never users. No increased risk is seen in women beyond 5 years after stopping HRT. There was no interaction between previous use of oral contraceptives and later HRT use. © 2001 Cancer Research Campaign www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Brinton, LA, Hoover, R & Fraumeni, JF (1986). Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer, 54, 825–832.
Brinton, LA, Brogan, DR, Coates, RJ, Swanson, CA, Potischman, N & Stanford, JL (1998). Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy. Menopause, 5, 145–151.
Colditz, GA, Hankinson, SE, Hunter, DJ, Willett, WC, Manson, JE, Stampfer, MJ, Hennekens, C, Rosner, B & Speizer, FE (1995). The use of estrogens and progestins and the risk of breast cancer in postmenopausal women [see comments]. N Engl J Med, 332, 1589–1593.
Collaborative Group on Hormonal Factors in Breast Cancer (1997). Breast cancer and hormone replacement therapy: collaborative re-analysis of data from 49 epidemiological studies involving 51, 977 women with breast cancer and 107,283 women without breast cancer. Lancet, 350, 1047–1059.
Genazzani, A & Gambacciani, M (1999). Hormone replacement therapy; the perspective for the 21st century. Maturitas, 32, 11–17.
Holli, K, Isola, J & Cuzick, J (1998). Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol, 16, 3115–3120.
Hunt, K, Vessey, M & McPherson, K (1990). Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol, 97, 1080–1086.
Jernström, H, Frenander, J, Fernö, M & Olsson, H (1999). Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never use among 984 breast cancer patients. Br J Cancer, 80, 9, 1453–1458.
Kelsey, JL & Whittemore, AS (1994). Epidemiology and primary prevention of cancers of the breast, endometrium, and ovary. A brief overview. Ann Epidemiol, 4, 89–95.
Lando, JF, Heck, KE & Brett, KM (1999). Hormone replacement therapy and breast cancer risk in a nationally representative cohort. Am J Prev Med, 17, 176–180.
Li, CI, Anderson, BO, Porter, P, Holt, SK, Daling, JR & Moe, RE (2000a). Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer, 88, 2561–2569.
Li, CI, Weiss, NS, Stanford, JL & Daling, JR (2000b). Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer, 88, 2570–2577.
Magnusson, C, Holmberg, L, Norden, T, Lindgren, A & Persson, I (1996). Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat, 38, 325–334.
Magnusson, C, Baron, JA, Correia, N, Bergstrom, R, Adami, HO & Persson, I (1999). Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer, 81, 339–344.
Mills, PK, Beeson, WL, Phillips, RL & Fraser, GE (1989). Prospective study of exogenous hormone use and breast cancer in Seventh-day Adventists. Cancer, 64, 591–597.
O’Connor, IF, Shembekar, MV & Shousha, S (1998). Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study. J Clin Pathol, 51, 935–938.
Persson, I (1996). Cancer risk in women receiving estrogen-progestin replacement therapy. Maturitas, 23, S37–S45.
Persson, I, Bergkvist, L, Lindgren, C & Yuen, J (1997). Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: evidence of confounding by exposure characteristics. J Clin Epidemiol, 50, 611–618.
Pike, MC & Ross, RK (2000). Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer [In Process Citation]. Steroids, 65, 659–664.
Risch, HA & Howe, GR (1994). Menopausal hormone usage and breast cancer in Saskatchewan: a record-linkage cohort study. Am J Epidemiol, 139, 670–683.
Ross, RK, Paganini-Hill, A, Wan, PC & Pike, MC (2000). Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin [see comments]. J Natl Cancer Inst, 92, 328–332.
Schairer, C, Gail, M, Byrne, C, Rosenberg, PS, Sturgeon, SR, Brinton, LA & Hoover, RN (1999). Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst, 91, 264–270.
Schairer, C, Lubin, J, Troisi, R, Sturgeon, S, Brinton, L & Hoover, R (2000). Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk [see comments]. Jama, 283, 485–491.
Torgerson, DJ & Reid, DM (1999). The pharmacoeconomics of hormone replacement therapy. Pharmacoeconomics, 16, 9–16.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Olsson, H., Bladström, A., Ingvar, C. et al. A population-based cohort study of HRT use and breast cancer in southern Sweden. Br J Cancer 85, 674–677 (2001). https://doi.org/10.1054/bjoc.2001.1899
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.1899
Keywords
This article is cited by
-
Modifiable risk factors in women at high risk of breast cancer: a systematic review
Breast Cancer Research (2023)
-
Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy
Familial Cancer (2018)
-
Hormone-related pathways and risk of breast cancer subtypes in African American women
Breast Cancer Research and Treatment (2015)
-
A candidate gene approach to searching for low-penetrance breast and prostate cancer genes
Nature Reviews Cancer (2005)
-
Factors Modifying the Association Between Hormone-Replacement Therapy and Breast Cancer Risk
European Journal of Epidemiology (2005)
